NOVO NORDISK A/S

NYSE: NVO (Novo Nordisk A/S)

Kemas kini terakhir: 04 Mar, 3:20AM

36.66

-1.10 (-2.91%)

  • 1H -2.91%
  • 5H 0.00%
  • 1B -25.08%
  • 6B -33.19%
  • Tahun Ke Tarikh -30.02%
  • 1T -50.98%
  • 5T 3.25%
Penutupan Terdahulu 37.76
Buka 36.37
Jumlah Dagangan 33,017,581
Purata Dagangan (3B) 23,631,825
Modal Pasaran 162,948,579,328
Harga / Pendapatan (P/E TTM) 10.13
Harga / Pendapatan (P/E Ke hadapan) 10.82
Harga / Jualan (P/S) 3.68
Harga / Buku (P/B) 5.86
Julat 52 Minggu
35.85 (-2%) — 91.90 (150%)
Tarikh Pendapatan 6 May 2026
Hasil Dividen (DY TTM) 3.00%
Margin Keuntungan 34.51%
Margin Operasi (TTM) 49.68%
EPS Cair (TTM) 3.67
Pertumbuhan Hasil Suku Tahunan (YOY) 19.50%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 14.30%
Jumlah Hutang/Ekuiti (D/E MRQ) 85.70%
Nisbah Semasa (MRQ) 0.740
Aliran Tunai Operasi (OCF TTM) 131.24 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 77.73 B
Pulangan Atas Aset (ROA TTM) 23.29%
Pulangan Atas Ekuiti (ROE TTM) 88.12%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Bercampur
Drug Manufacturers - General (Global) Menaik Bercampur
Stok Novo Nordisk A/S Menaik Menurun

AISkor Stockmoo

2.0
Konsensus Penganalisis 3.0
Aktiviti Orang Dalam NA
Volatiliti Harga 5.0
Purata Bergerak Teknikal 2.5
Osilator Teknikal -2.5
Purata 2.00

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
NVO 163 B 3.00% 10.13 5.86
NVS 326 B 2.46% 23.58 6.66
LLY 895 B 0.63% 43.47 33.65
JNJ 585 B 2.14% 22.00 7.20
ABBV 407 B 0.71% 97.09 50.46
MRK 306 B 0.65% 17.01 5.65

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Core
% Dimiliki oleh Orang Dalam 0.01%
% Dimiliki oleh Institusi 9.85%

Pemilikan

Nama Tarikh Syer Dipegang
Everett Harris & Co /Ca/ 31 Dec 2025 6,407,366
Julat 52 Minggu
35.85 (-2%) — 91.90 (150%)
Julat Harga Sasaran
41.00 (11%) — 73.50 (100%)
Tinggi 73.50 (CICC, 100.49%) Beli
Median 57.25 (56.17%)
Rendah 41.00 (Goldman Sachs, 11.84%) Pegang
Purata 57.25 (56.17%)
Jumlah 1 Beli, 1 Pegang
Harga Purata @ Panggilan 48.29
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Goldman Sachs 02 Mar 2026 41.00 (11.84%) Pegang 37.76
CICC 09 Jan 2026 73.50 (100.49%) Beli 58.81

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
05 Mar 2026 CNBC Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.
24 Feb 2026 CNBC Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients
11 Feb 2026 CNBC Novo Nordisk CEO sees 15 million patient opportunity in Medicare coverage for obesity drugs
11 Feb 2026 CNBC Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start
09 Feb 2026 CNBC FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims
09 Feb 2026 CNBC Super Bowl 60 recap: Rewatch all the top commercials from advertising's biggest night
09 Feb 2026 CNBC Novo Nordisk sues Hims & Hers over copycat versions of Wegovy drugs; Hims stock falls 18%
06 Feb 2026 CNBC White House launches direct-to-consumer drug site TrumpRx. Here's what to know
05 Feb 2026 Pengumuman Novo Nordisk issues statement on illegal mass compounding and deceptive advertising by Hims & Hers
05 Feb 2026 Pengumuman Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
05 Feb 2026 Pengumuman Lexaria Announces Positive Final Results From Human Pilot Study #5
04 Feb 2026 CNBC Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
04 Feb 2026 Pengumuman Novo Nordisk files annual report with the SEC
04 Feb 2026 Pengumuman Novo Nordisk has published its annual report for 2025
04 Feb 2026 Pengumuman Novo Nordisk initiates 2026 share repurchase programme
04 Feb 2026 CNBC Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
03 Feb 2026 CNBC Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
03 Feb 2026 Pengumuman Novo Nordisk releases 2026 sales and operating profit outlook
03 Feb 2026 Pengumuman Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025
02 Feb 2026 Pengumuman Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
31 Jan 2026 Pengumuman New employee representative on the Board of Directors of Novo Nordisk A/S
30 Jan 2026 CNBC Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections
30 Jan 2026 CNBC Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch
23 Jan 2026 CNBC What obesity drugmakers see next in the market: More pills, easier access and drug combinations
20 Jan 2026 CNBC Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry
20 Jan 2026 Pengumuman Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes
16 Jan 2026 CNBC Novo Nordisk shares rise 8% after Wegovy obesity pill has 'solid' launch
10 Jan 2026 CNBC 2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market
09 Jan 2026 CNBC Amazon Pharmacy starts offering Novo Nordisk's Wegovy weight loss pill
05 Jan 2026 Pengumuman Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America
05 Jan 2026 CNBC First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. 
31 Dec 2025 Pengumuman Novo Nordisk A/S: China’s Supreme People’s Court delivers a positive ruling on the semaglutide compound patent
22 Dec 2025 Pengumuman Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management
22 Dec 2025 CNBC FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
19 Dec 2025 CNBC Wall Street banked on a flurry of deals under Trump in 2025. It wasn't that simple
12 Dec 2025 Pengumuman Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss
Papar semua
Hasil Dividen (DY TTM) 3.00%
Purata Hasil Dividen 5T 2.17%
Nisbah Pembayaran 47.09%
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
31 Mar 2025 05 Feb 2025 08 Apr 2025 1.099206 Tunai
16 Aug 2024 06 Aug 2024 26 Aug 2024 0.5126402 Tunai
22 Mar 2024 31 Jan 2024 02 Apr 2024 0.92985 Tunai
18 Aug 2023 10 Aug 2023 29 Aug 2023 0.8835613 Tunai
24 Mar 2023 02 Feb 2023 04 Apr 2023 1.1887415 Tunai
12 Aug 2022 04 Aug 2022 23 Aug 2022 0.5835507 Tunai
25 Mar 2022 02 Mar 2022 05 Apr 2022 1.022423 Tunai
16 Aug 2021 - 25 Aug 2021 0.5502889 Tunai
26 Mar 2021 - 07 Apr 2021 0.922122 Tunai
14 Aug 2020 06 Aug 2020 25 Aug 2020 0.5177774 Tunai
27 Mar 2020 06 Feb 2020 07 Apr 2020 0.7826048 Tunai
16 Aug 2019 10 Aug 2019 27 Aug 2019 0.449438 Tunai
22 Mar 2019 05 Feb 2019 02 Apr 2019 0.777006 Tunai
17 Aug 2018 09 Aug 2018 28 Aug 2018 0.462327 Tunai
23 Mar 2018 24 Mar 2018 03 Apr 2018 0.805982 Tunai
17 Aug 2017 - 29 Aug 2017 0.33589 Tunai
23 Mar 2017 - 04 Apr 2017 0.479369 Tunai
11 Aug 2016 - 23 Aug 2016 0.331026 Tunai
18 Mar 2016 - 30 Mar 2016 0.69943 Tunai
19 Mar 2015 - 31 Mar 2015 0.532885 Tunai
21 Mar 2014 - 02 Apr 2014 0.606122 Tunai
21 Mar 2013 - 02 Apr 2013 2.264307 Tunai
22 Mar 2012 - 03 Apr 2012 1.831902 Tunai
24 Mar 2011 - 05 Apr 2011 1.357901 Tunai
25 Mar 2010 - 07 Apr 2010 0.978615 Tunai
19 Mar 2009 - 31 Mar 2009 0.781532 Tunai
13 Mar 2008 - 25 Mar 2008 0.678462 Tunai
08 Mar 2007 - 20 Mar 2007 0.891779 Tunai
09 Mar 2006 - 21 Mar 2006 0.691753 Tunai
10 Mar 2005 - 22 Mar 2005 0.61725 Tunai
17 Mar 2004 - 29 Mar 2004 0.52096 Tunai
26 Mar 2003 - 07 Apr 2003 0.37647 Tunai
13 Mar 2002 - 25 Mar 2002 0.2848 Tunai
21 Mar 2001 - 02 Apr 2001 0.5681 Tunai
24 Mar 2000 - 06 Apr 2000 0.4672 Tunai
25 Mar 1999 - 06 Apr 1999 0.4182 Tunai
27 Mar 1998 - 08 Apr 1998 0.3051 Tunai
25 Apr 1997 - 07 May 1997 0.239 Tunai
01 May 1996 - 14 May 1996 0.1806 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 1.10 1 2.16
2024 1.44 2 1.68
2023 2.07 2 2.00
2022 1.61 2 2.37
2021 1.47 2 2.63
2020 1.30 2 3.72
2019 1.23 2 4.24
2018 1.27 2 5.51
2017 0.815 2 3.04
2016 1.03 2 5.75
2015 0.533 1 1.84
2014 0.606 1 2.86
2013 2.26 1 12.26
2012 1.83 1 11.22
2011 1.36 1 11.78
2010 0.979 1 8.69
2009 0.782 1 12.24
2008 0.678 1 13.20
2007 0.892 1 13.75
2006 0.692 1 16.54
2005 0.617 1 21.94
2004 0.521 1 19.20
2003 0.376 1 18.38
2002 0.285 1 19.71
2001 0.568 1 28.33
2000 0.467 1 26.40
1999 0.418 1 32.36
1998 0.305 1 22.94
1997 0.239 1 16.57
1996 0.181 1 19.32
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda